CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
被遗忘的幸存者：非霍奇金淋巴瘤生存状况综合综述
英文原题：The forgotten survivor: A comprehensive review on Non-Hodgkin lymphoma survivorship.
查看英文原题
The forgotten survivor: A comprehensive review on Non-Hodgkin lymphoma survivorship.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
非霍奇金淋巴瘤（NHL）幸存者的数量正在增加。随着NHL治疗的进步，关注这些幸存者可能面临的挑战至关重要。NHL幸存者管理需考虑三大主要方面，包括生活质量和对未来的不确定性、可能的身体健康并发症（包括心血管疾病、不孕症和后续肿瘤），以及新型NHL治疗方法及其潜在并发症的影响。后者包括CAR-T 细胞疗法、单克隆抗体、检查点抑制剂和造血干细胞移植。在本报告中，我们旨在阐明这些方面，并讨论NHL的幸存者照护计划。
展开英文摘要原文
The number of non-Hodgkin lymphoma (NHL) survivors is increasing. With the advancement of NHL therapies, it is crucial to focus on the challenges these survivors may face. Three main categories are to be considered in NHL survivorship, including quality of life and uncertainty about the future, possible physical health complications (including cardiovascular disease, infertility, and subsequent neoplasms), and the impact of novel NHL treatments and their potential complications.
The latter includes CAR T-cell therapy, monoclonal antibodies, checkpoint inhibitors, and hematopoietic stem cell transplantation. In this report, we aim to shed the light on these aspects and to discuss survivorship care plan for NHL.
论文信息
- 作者
- Alabdaljabar MS、Durani U、Thompson CA、Constine LS、Hashmi SK
- 第一作者单位
- Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA.United States
- 通讯作者单位
- Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA.United States
- 文献类型
- 综述
- 期刊
- American journal of hematology2022 Dec
- 原文标识
- PubMed 36069675 · DOI 10.1002/ajh.26719